Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU1-24P is a pseudogene belonging to the U1 small nuclear RNA (snRNA) gene family and is annotated in the human genome as a non-coding RNA[4]. Pseudogenes are gene sequences that resemble real genes but typically include base changes, deletions, or insertions that render them nonfunctional; for U1 snRNA, most pseudogenes encode imperfect or incomplete copies that neither translate into protein nor produce functional RNAs[2]. The U1 snRNA family is central to pre-mRNA splicing and transcriptome regulation[1][2], but pseudogenes like RNU1-24P by definition do not encode the functional RNA sequence nor participate in these processes[2][4]. While some pseudogenes can perform regulatory or RNA-based activities, there is currently no evidence that RNU1-24P or its transcript serves a direct biological function or acts as a pharmacological target. Its designation as a “pseudogene” means it is not a valid therapeutic target, receptor, enzyme, or transporter[2][4]. The presence and misclassification of U1 pseudogenes have been a subject of genomic annotation efforts; most do not appear transcriptionally active or functionally relevant in standard human tissues[2]. Databases including NCBI Gene and Ensembl list RNU1-24P as a pseudogene entry; there are no known therapeutic, diagnostic, or drug-interaction roles for this entity[4]. If the query is seeking a molecular target for drug development or biological assays, RNU1-24P should be excluded, as it fails to meet any criteria for a therapeutic or functional RNA target. The target name is correct per database convention, but its biological and pharmacological relevance is null.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U1 small nuclear 24, pseudogene (RNU1-24P).